• In early January 2026, Oklo announced a partnership with Meta to advance a 1.2 GW nuclear power campus in Pike County, Ohio, alongside a separate U.S. Department of Energy agreement to build a radioisotope pilot facility under the Reactor Pilot Program.
• Together, these deals position Oklo at the junction of clean data center power and domestic medical isotope production, expanding its potential customer base beyond utilities.
• Next, we’ll examine how Meta’s prepayment-backed Ohio project could reshape Oklo’s investment narrative despite the recent 7-day share price decline.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

What Is Oklo's Investment Narrative?

To own Oklo here, you have to believe that advanced nuclear can become a viable, contracted solution for data centers and critical infrastructure long before it looks like a conventional utility business. The Meta deal and DOE radioisotope pilot do meaningfully shape that story: Meta’s prepayment mechanism helps address one of the near term catalysts, which is securing funding and commercial validation for the first Aurora projects, while the DOE agreement gives Oklo a second leg in medical and research isotopes. At the same time, they highlight the core risks that have not gone away: no current revenue, a long runway to meaningful operations, execution and regulatory complexity, and a share price that has been volatile after a very large one year total return. The recent 7 day pullback suggests the news has not removed those tensions, just reframed them.

However, one key risk for shareholders is only becoming more pressing. Upon reviewing our latest valuation report, Oklo's share price might be too optimistic.

Exploring Other Perspectives

Sixty nine Simply Wall St Community fair value estimates span roughly US$11.6 to US$115.8, underscoring just how far opinions spread on Oklo. Set against that, the Meta prepayment structure and DOE pilot support sharpen the focus on execution timelines and regulatory outcomes, which could be pivotal for how those forecasts eventually stack up.

Explore 69 other fair value estimates on Oklo - why the stock might be worth less than half the current price!

Build Your Own Oklo Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Oklo research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Oklo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oklo's overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.